ALGS (Aligos Therapeutics, Inc.) Quarterly EPS earnings growth

Aligos Therapeutics (ALGS) - corporate logo

Aligos Therapeutics (ALGS) develops advanced methods for combating chronic viral liver diseases. Quarterly earnings per share (EPS) growth clearly demonstrates the dynamics of this process, with the indicator standing at 31.50. High R&D expenditures and FDA certification create significant barriers to entry. Simultaneously, the company is implementing ESG standards to ensure ethical research and environmentally sustainable laboratories.

aligos.com (ALGS) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for Aligos Therapeutics (ALGS)

- share price and consensus valuation forecast:
Stock Quotes aligos.com|ALGS - Price Target Chart
- business market valuation indicators:
Market Capitalization Aligos|ALGS - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Aligos Therapeutics|ALGS - Accounting Value of Company|Market Capitalization to Book Value Ratio aligos.com|ALGS - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Aligos Therapeutics|ALGS - Long-Term Debt to Equity|Short-Term Debt to Capital aligos.com|ALGS - Company Total Debt Obligations|Debts to Book Capitalization Aligos|ALGS - Long-Term Indebtedness|Company Short-Term Debt Aligos Therapeutics|Quick Liquidity aligos.com
- earnings and market multiples details:
ALGS - Net Financial Result|Future Profit Aligos Therapeutics|ALGS - Company Value to Net Income|Projected Price to Earnings aligos.com|ALGS - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Aligos|ALGS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aligos Therapeutics|ALGS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aligos.com|ALGS - Earnings per share increase in current year|Earnings growth forecast for next year Aligos Therapeutics
- sales revenue and business income indicators:
ALGS - Revenue and Sales Volume|Company Projected Revenue aligos.com|ALGS - Price-to-Sales Ratio|Forward P/S Multiple Aligos
Analysis of all company metrics:Aligos Therapeutics Inc. - ALGS
Manufactured product of Aligos Therapeutics

Investors are verifying the issuer's resilience through earnings per share dynamics, assessing the business's ability to generate cash flow. The current value of 31.50 regarding the quarterly EPS growth trend reflects the rate of change in net income, which for the biopharmaceutical sector of Aligos Therapeutics (ALGS) is more critical than macro cycles, as it correlates directly with the success of clinical trials and R&D cost efficiency.

Competitors of Aligos Therapeutics

ARWR (Arrowhead Pharmaceuticals, Inc.) - Year-over-year net earnings per share growth for the last 12 months|MIRM (Mirum Pharmaceuticals, Inc.) - Year-over-year earnings per share growth for the last twelve months|DVAX (Dynavax Technologies) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tekmira Pharmaceuticals ABUS|Year-over-year earnings per share growth for the last twelve months Inventiva S.A. (IVA)|GYRE (gyretx.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ASMB (Assembly Biosciences, Inc.)|Quarterly EPS earnings growth Galectin Therapeutics, Inc. GALT|GNFT - Year-over-year earnings per share growth for the last twelve months|DRRX: Year-over-year earnings per share growth for the last twelve months|BIVI: Quarterly EPS earnings growth|GLMD - Year-over-year net earnings per share change for the last twelve months|NDRA (ENDRA Life Sciences Inc.) - Quarterly EPS earnings growth|HEPA - Net earnings per share growth for the trailing year